Pay in 4 interest-free payments of $7.06 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Trials are expanding data on the benefits of GLP-1s in chronic kidney disease and heart failure with preserved ejection fraction (HFpEF)
The authors observed that "early-stage disease may represent an optimal treatment window for maximizing therapeutic effects," while stressing that the concept requires validation in prospective trials designed specifically for that population
investigates how steroid replacement in adrenal insufficiency affects hypoglycemia in patients with type 1 diabetes mellitus (T1D)
Its a potent inhibitor of melanin production, working by reducing the activity of tyrosinase
As treatment options expand in the increasingly competitive weight-loss drug market, doctors advise that decisions will continue to hinge on considerations of effectiveness, safety, tolerability, and cost
US$ 27.13
US$ 27.56
US$ 27.17
US$ 21.03
